Needham & Company
View Older Stories
-
Cardiovascular Systems (CSII) PT Raised to $50 at Needham & Company
-
Cardiovascular Systems, Inc. to Present at the 23rd Annual Needham Virtual Growth Conference
-
UPDATE: Needham & Company Upgrades Cardiovascular Systems (CSII) to Buy
-
Cardiovascular Systems, Inc. to Participate at Three Upcoming Investor Conferences
-
Cardiovascular Systems, Inc. to Present at Three Upcoming Investor Conferences
-
UPDATE: Needham & Company Downgrades Cardiovascular Systems (CSII) to Hold
-
Cardiovascular Systems (CSII): Raising PT On Margin Expansion and Japan - Needham
-
Needham & Company Reiterates Buy Rating and $32 PT on Cardiovascular Systems (CSII) Following Pump Recall; 'A Buying Opportunity'
-
Cardiovascular Systems (CSII) PT Raised to $32 at Needham & Company Following 2Q Earnings Report
-
Pre-Open Stock Movers 08/22: (CIFC) (ISIL) (MDVN) Higher; (STRP) (MRO) (WDAY) Lower (more...)
-
Needham & Company Raises Price Target on Cardiovascular Systems (CSII) to $27 Following 4Q Beat
-
Needham & Company Raises price Target on Cardiovascular Systems (CSII) Following Investor meeting
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Cardiovascular Systems to Present at the 15th Annual Needham Healthcare Conference
-
Unusual 11 Mid-Day Movers 4/1: (SKYS) (CSII) (AKTX) Higher; (ROVI) (UPL) (AKER) Lower
-
Cardiovascular Systems (CSII) Surges on Guidance, Upgrade
-
Pre-Open Stock Movers 04/01: (CSII) (VJET) (TSLA) Higher; (BBRY) (SUNE) (GNCA) Lower (more...)
-
Needham & Company Upgrades Cardiovascular Systems (CSII) to Buy
-
Pre-Open Stock Movers 01/22: (NRX) (EGHT) (CHK) Higher; (CSII) (LGCY) (DGII) Lower (more...)
-
Needham & Company Downgrades Cardiovascular Systems (CSII) to Underperform
-
Cardiovascular Systems (CSII) Guides Low 2Q16 Given Lingering Headwinds; Needham & Company Reiterates Buy
-
Notable Analyst Rating Changes 10/8: (YUM) (CPGX) (INFN) Upgraded; (CSII) (CEQP) (NBR) Downgraded
-
Needham & Company Downgrades Cardiovascular Systems (CSII) to Buy
-
Needham & Company Cuts Price Target on Cardiovascular Systems (CSII) to $37 Following 4Q15 Results
-
Needham & Company Comments on Sector Implications Amid Medtronic (MDT)/Covidien (COV) Megadeal
-
Notable Analyst Rating Changes 05/12: (NMBL) (TWTR) (ACT) Upgraded; (AMRN) (DE) (RL) Downgraded
-
Needham & Company Starts Cardiovascular Systems (CSII) at Strong Buy